C. Difficile Infection Video Perspectives

Allegretti reports serving as a consultant for Abbvie, Adiso, Bristol Myer Squibb, Ferring, Finch Therapeutics, Iterative Scopes, Janssen, Merck, Pfizer, and Seres Therapeutics; as a speaker for Abbvie, BMS, and Janssen; and has received research support from Merck and Pfizer.

May 01, 2023

1 min watch

Save

VIDEO: Disparities in care for patients with C. difficile infection

Transcript

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The main disparities right now, again, are around access, so depending on where you live, you may have access to a center that offers FMT or not. I think while we are still operating in the non-FDA-approved, more traditional FMT space and that is still being offered.

Now we have FDA-approved products, so presumably, there will be better access with FDA-approved products that any clinician can prescribe. And so then, the new disparities will be around what your insurance coverage is and are these therapies affordable. I think because we don’t really know what the coverage is going to look like for a lot of these therapies, and again, it will depend a lot about which insurance you have, OpenBiome has committed to staying open to have that sort of alternative treatment available for patients. They have reassured me that they will continue to be offering this therapy, again, as long as they’re allowed to, to hopefully mitigate some of those disparities.